Seasonal Influenza Vaccine Supply for the U.S. 2015-2016 Influenza Season
| ||
How much influenza vaccine is projected to be available for the 2015-16 influenza season?
Flu vaccine is produced by private manufacturers, so supply depends on manufacturers. For this season, manufacturers have projected they will provide between 171 to 179 million doses of vaccine for the U.S. market. (Projections may change as the season progresses.)
How much thimerosal-free influenza vaccine is expected to be available for the 2015-16 season?
For the 2015-16 season, manufacturers will produce influenza vaccines containing thimerosal and some vaccines that do not contain thimerosal.
Approximately 116 to 118 million doses of thimerosal-free influenza vaccine will be produced for the 2015-2016 flu season.
Can I still buy influenza vaccine for the 2015-16 season?
Influenza vaccine pre-booking typically occurs between January and March, though most preparations of vaccine should still be available for purchase. Providers should contact distributors and local vendors about remaining supply. Information about manufacturers and distributors who still have influenza vaccine available for sale can be found at http://www.preventinfluenza.org/ivats/
What can we anticipate in terms of the timing of vaccine availability for the 2015-16 season?
The timing of vaccine availability depends on when production is completed. Some influenza vaccine shipments have already begun and will continue throughout September and October until all of the vaccine is distributed.
Are all influenza vaccines the same?
Different influenza vaccine preparations have different indications as licensed by the FDA. See the table below for an overview of these indications.
Top of PageTABLE. Influenza vaccines — United States, 2015–16 influenza season*
Trade name | Manufacturer | Presentation | Mercury content from thimerosal (µg Hg/0.5 mL) | Ovalbumin content (µg/0.5mL) | Age indications | Latex | Route |
Inactivated influenza vaccine, quadrivalent (IIV4), standard dose Contraindications*: Severe allergic reaction to any vaccine component, including egg protein, or after previous dose of any influenza vaccine. Precautions*: Moderate to severe acute illness with or without fever; history of Guillain-Barré syndrome within 6 weeks of receipt of influenza vaccine. | |||||||
Fluarix Quadrivalent | GlaxoSmithKline | 0.5 mL single-dose prefilled syringe | — | ≤0.05 | ≥3 yrs | No | IM† |
FluLaval Quadrivalent | ID Biomedical Corp. of Quebec (distributed by GlaxoSmithKline) | 5.0 mL multi-dose vial | <25 | ≤0.3 | ≥3 yrs | No | IM† |
Fluzone Quadrivalent | Sanofi Pasteur | 0.25 mL single-dose prefilled syringe | — | § | 6–35 mos | No | IM† |
0.5 mL single-dose prefilled syringe | — | § | ≥36 mos | No | IM† | ||
0.5 mL single-dose vial | — | § | ≥36 mos | No | IM† | ||
5.0 mL multidose vial | 25 | § | ≥6 mos | No | IM† | ||
Fluzone Intradermal¶ Quadrivalent | Sanofi Pasteur | 0.1 mL single-dose prefilled microinjection system | — | § | 18–64 yrs | No | ID** |
Inactivated influenza vaccine, trivalent (IIV3), standard dose Contraindications*: Severe allergic reaction to any vaccine component, including egg protein, or after previous dose of any influenza vaccine. Precautions*: Moderate to severe acute illness with or without fever; history of Guillain-Barré syndrome within 6 weeks of receipt of influenza vaccine. | |||||||
Afluria | bioCSL | 0.5 mL single-dose prefilled syringe | — | <1 | ≥9 yrs†† | No | IM† |
5.0 mL multi-dose vial | 24.5 | <1 | ≥9 yrs†† via needle; 18-64 years via jet injector | No | IM† | ||
Fluvirin | Novartis Vaccines and Diagnostics | 0.5 mL single-dose prefilled syringe | ≤1 | ≤1 | ≥4 yrs | Yes§§ | IM† |
5.0 mL multi-dose vial | 25 | ≤1 | ≥4 yrs | No | IM† | ||
Fluzone | Sanofi Pasteur | 5.0 mL multi-dose vial | 25 | § | ≥6 mos | No | IM† |
Inactivated influenza vaccine, cell-culture-based (ccIIV3), standard dose Contraindications*: Severe allergic reaction to any vaccine component, including egg protein, or after previous dose of any influenza vaccine. Precautions*: Moderate to severe acute illness with or without fever; history of Guillain-Barré syndrome within 6 weeks of receipt of influenza vaccine. | |||||||
Flucelvax | Novartis Vaccines and Diagnostics | 0.5 mL single-dose prefilled syringe | — | ¶¶ | ≥18 yrs | Yes§§ | IM† |
Inactivated influenza vaccine, trivalent (IIV3), high dose Contraindications*: Severe allergic reaction to any vaccine component, including egg protein, or after previous dose of any influenza vaccine. Precautions*: Moderate to severe acute illness with or without fever; history of Guillain-Barré syndrome within 6 weeks of receipt of influenza vaccine. | |||||||
Fluzone High-Dose*** | Sanofi Pasteur | 0.5 mL single-dose prefilled syringe | — | § | ≥65 yrs | No | IM† |
Recombinant influenza vaccine, trivalent (RIV3), standard dose Contraindications*: Severe allergic reaction to any vaccine component. Precautions*: Moderate to severe acute illness with or without fever; history of Guillain-Barré syndrome within 6 weeks of receipt of influenza vaccine. | |||||||
FluBlok | Protein Sciences | 0.5 mL single-dose vial | — | 0 | ≥18 yrs | No | IM† |
Live attenuated influenza vaccine, quadrivalent (LAIV4) Contraindications*: Severe allergic reaction to any vaccine component, including egg protein, or after previous dose of any influenza vaccine. Concomitant use of aspirin or aspirin-containing medications in children and adolescents. In addition, ACIP recommends LAIV4 not be used for pregnant women, immunosuppressed persons, persons with egg allergy, and children aged 2 through 4 years who have asthma or who have had a wheezing episode noted in the medical record within the past 12 months, or for whom parents report that a health care provider stated that they had wheezing or asthma within the last 12 months. LAIV4 should not be administered to persons who have taken influenza antiviral medications within the previous 48 hours. Persons who care for severely immunosuppressed persons who require a protective environment should not receive LAIV4, or should avoid contact with such persons for 7 days after receipt. Precautions*: Moderate to severe acute illness with or without fever; history of Guillain-Barré syndrome within 6 weeks of receipt of influenza vaccine; asthma in persons aged 5 years and older; medical conditions which might predispose to higher risk for complications attributable to influenza. | |||||||
FluMist Quadrivalent††† | MedImmune | 0.2 mL single-dose prefilled intranasal sprayer | — | <0.24 (per 0.2 mL) | 2–49 yrs | No | IN |
Abbreviations: ACIP = Advisory Committee on Immunization Practices; ID = intradermal; IM = intramuscular; IN = intranasal.
* Immunization providers should check Food and Drug Administration-approved prescribing information for 2015–16 influenza vaccines for the most complete and updated information, including (but not limited to) indications, contraindications, warnings, and precautions. Package inserts for U.S.-licensed vaccines are available atwww.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm093833.htm.
† For adults and older children, the recommended site for intramuscular influenza vaccination is the deltoid muscle. The preferred site for infants and young children is the anterolateral aspect of the thigh. Specific guidance regarding site and needle length for intramuscular administration may be found in the ACIP General Recommendations on Immunization, available at www.cdc.gov/mmwr/preview/mmwrhtml/rr6002a1.htm.
§ Available upon request from Sanofi Pasteur (1–800–822–2463 or MIS.Emails@sanofipasteur.com).
¶ Quadrivalent inactivated influenza vaccine, intradermal: a 0.1-mL dose contains 9 µg of each vaccine antigen (36 µg total).
** The preferred injection site is over the deltoid muscle. Fluzone Intradermal Quadrivalent is administered using the delivery system included with the vaccine.
†† Age indication per package insert is ≥5 years; however, ACIP recommends Afluria not be used in children aged 6 months through 8 years because of increased risk of febrile reactions noted in this age group with bioCSL's 2010 Southern Hemisphere IIV3. If no other age-appropriate, licensed inactivated seasonal influenza vaccine is available for a child aged 5 through 8 years who has a medical condition that increases the child's risk for influenza complications, Afluria can be used; however, providers should discuss with the parents or caregivers the benefits and risks of influenza vaccination with Afluria before administering this vaccine. Afluria may be used in persons aged ≥9 years.
§§ Syringe tip cap may contain natural rubber latex.
¶¶ Information not included in package insert. Estimated to contain <50 femtograms (5x10-8 µg) of total egg protein (of which ovalbumin is a fraction) per 0.5 mL dose of Flucelvax.
*** Trivalent inactivated influenza vaccine, high-dose: a 0.5-mL dose contains 60 µg of each vaccine antigen (180 µg total).
††† FluMist is shipped refrigerated and stored in the refrigerator at 35°F–46°F (2°C–8°C) after arrival in the vaccination clinic. The dose is 0.2 mL divided equally between each nostril. Health care providers should consult the medical record, when available, to identify children aged 2 through 4 years with asthma or recurrent wheezing that might indicate asthma. In addition, to identify children who might be at greater risk for asthma and possibly at increased risk for wheezing after receiving LAIV, parents or caregivers of children aged 2 through 4 years should be asked: "In the past 12 months, has a health care provider ever told you that your child had wheezing or asthma?" Children whose parents or caregivers answer "yes" to this question and children who have asthma or who had a wheezing episode noted in the medical record within the past 12 months should not receive FluMist.
.png)
No hay comentarios:
Publicar un comentario